TARS
Tarsus Pharmaceuticals Inc
75.70$
-0.4%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q4 17 | Q1 18 | Q2 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | – | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| – | – | – | – | – | – | – | – | – | – | – | – | 3.9% | 3.3% | 5.2% | -7.1% | 6.1% | 3.4% | – | 4.0% | 10.2% | 2.1% | 20.1% | 9.3% | 6.0% | 7.4% | 6.7% | 7.4% | 6.7% | 6.1% | 20.7% | 7.2% | 5.8% | 7.0% | 9.4% | |
| – | – | – | – | – | – | – | – | – | – | – | – | 96.1% | 96.7% | 94.8% | 107.1% | 93.9% | 96.6% | – | 96.0% | 89.8% | -2.1% | 79.9% | 90.7% | 94.0% | 92.6% | 93.3% | 92.6% | 93.3% | 93.9% | 79.3% | 92.8% | 94.2% | 93.0% | 90.6% | |
| – | – | – | – | – | – | – | – | – | – | – | – | 48.6% | 32.7% | 823.3% | 2,378.1% | 2,241.4% | 62.9% | – | 100.3% | 494.2% | 82.1% | 647.0% | 101.8% | 43.7% | 30.2% | 25.2% | 25.4% | 18.4% | 15.2% | 13.7% | 11.9% | 13.8% | 17.8% | 14.5% | |
| – | – | – | – | – | – | – | – | – | – | – | – | 15.4% | 30.9% | 538.0% | 2,003.6% | 1,474.2% | 67.9% | – | 146.3% | 603.8% | 132.7% | 1,620.7% | 502.4% | 186.8% | 144.1% | 120.3% | 103.9% | 108.5% | 100.3% | 91.5% | 86.2% | 84.2% | 86.7% | 86.8% | |
| – | – | – | – | – | – | – | – | – | – | – | – | 64.1% | 63.6% | 1,361.3% | 4,381.7% | 3,715.6% | 130.8% | – | 246.6% | 1,087.9% | 212.8% | 2,267.7% | 430.6% | 230.5% | 174.2% | 145.6% | 129.4% | 126.9% | 115.5% | 91.5% | 98.1% | 98.0% | 104.5% | 98.6% | |
| – | – | – | – | – | – | – | – | – | – | – | – | 32.0% | 33.1% | -1,266.5% | -4,274.6% | -3,621.7% | -34.2% | – | -150.6% | -998.1% | -214.8% | -2,187.9% | -339.9% | -136.5% | -81.6% | -52.3% | -36.8% | -33.5% | -21.6% | -12.2% | -5.3% | -3.8% | -11.4% | -8.0% | |
| – | – | – | – | – | – | – | – | – | – | – | – | 0.0% | 0.0% | 0.6% | 3.6% | 58.6% | 3.6% | – | 6.9% | 27.4% | 5.3% | 45.9% | 7.6% | 3.6% | 5.2% | 4.8% | 3.3% | 2.6% | 2.0% | 1.8% | 1.5% | 1.3% | 1.2% | 1.4% | |
| – | – | – | – | – | – | – | – | – | – | – | – | 32.0% | 29.0% | -1,293.4% | -4,377.8% | -3,754.5% | -37.6% | – | -136.0% | -936.8% | -205.7% | -2,092.4% | -320.4% | -129.4% | -81.6% | -48.7% | -34.8% | -32.1% | -19.8% | -10.6% | -4.2% | -5.8% | -9.1% | -7.3% | |
| – | – | – | – | – | – | – | – | – | – | – | – | 0.9% | 0.1% | -27.5% | 16.0% | 0.2% | 3.4% | – | -5.2% | -61.3% | -177.2% | -95.5% | 232.5% | -1.0% | – | – | – | – | – | – | 1.4% | -1.5% | 1.6% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | 30.8% | 28.6% | -1,265.9% | -4,393.8% | -3,754.7% | -37.6% | – | -136.0% | -936.8% | -205.7% | -2,092.4% | -320.4% | -129.4% | -81.6% | -48.7% | -34.8% | -32.1% | -19.8% | -10.6% | -5.5% | -4.3% | -10.7% | -7.7% | |
| – | – | – | – | – | – | – | – | – | – | – | – | 32.3% | 29.7% | -1,286.7% | -4,366.0% | -3,688.3% | -33.4% | – | -128.1% | -906.4% | -199.2% | -2,035.2% | -310.2% | -124.9% | -75.8% | -43.0% | -30.7% | -28.7% | -17.2% | -10.2% | -2.4% | -4.2% | -7.3% | -5.8% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.